AtriCure (ATRC) closed the last trading session at $32.25, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $49.89 indicates a 54.7% upside potential. The mean estimate comprises nine short-term price targets with a standard deviation of $6.37. While the lowest estimate of $40 indicates a 24% increase from the current price level, the most optimistic analyst expects the ...

Dream Finders Homes Inc. (DFH) closed the last trading session at $23.26, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.50 indicates a 26.8% upside potential. The mean estimate comprises three short-term price targets with a standard deviation of $4.44. While the lowest estimate of $26 indicates an 11.8% increase from the current price level, the most optimistic ...

Price, Consensus and EPS Surprise Ivanhoe Electric (IE) closed the last trading session at $6.80, gaining 5.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $14 indicates a 105.9% upside potential. The mean estimate comprises five short-term price targets with a standard deviation of $3.81. While the lowest estimate of $10 indicates a 47.1% increase from the current price level, ...

Shares of Intellia Therapeutics, Inc. (NTLA) have gained 14.9% over the past four weeks to close the last trading session at $7.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $40.08 indicates a potential upside of 408.6%. The mean estimate comprises 25 short-term price targets with a standard deviation of $26.66. While the lowest estimate of $9 indicates a 14.2% increase fr ...

Shares of Enanta Pharmaceuticals (ENTA) have gained 5.1% over the past four weeks to close the last trading session at $5.18, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15 indicates a potential upside of 189.6%. According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far mo ...

According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. MoonLake Immunotherapeutics (MLTX) closed the last trading session at $36.99, gaining 0.1% over the past four weeks, but there could be ...

Shares of NovoCure (NVCR) have gained 8% over the past four weeks to close the last trading session at $17.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $35.14 indicates a potential upside of 105.5%. The mean estimate comprises seven short-term price targets with a standard deviation of $6.74. While the lowest estimate of $27 indicates a 57.9% increase from the current pri ...

HMC currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Segmental Highlights For the three-month period, which ended on March 31, 2025, revenues from the Automobile segment decreased 2.8% year over year to ¥3.57 trillion ($23.4 billion) but topped our projection of ¥3.4 trillion. The segment registered an operating loss of ¥158.7 billion ($1.04 billion) as against an operating income of $100.1 billion in the corresponding quarter of fisc ...

Toyota (TM) reported fiscal fourth-quarter 2025 earnings per share of $3.39, which surpassed the Zacks Consensus Estimate of $2.92 but declined from the year-ago quarter's earnings of $4.99. Consolidated revenues came in at $81.09 billion, which beat the consensus mark of $78.47 billion and also grew from $74.56 billion in the year-ago quarter. Toyota had cash and cash equivalents (non-financial services businesses) of ¥6.09 trillion ($41.75 billion) as of March 31, 2025. Long-term debt (non-financial servi ...

ETFs in Focus Let's delve into each ETF below: Novo Nordisk (NVO) announced a significant partnership with Septerna (SEPN) , a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. Following the announcement, SEPN shares jumped 51%, while NVO shares gained a little 1.6%. This put the spotlight on healthcare ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal. Investors should keep a close eye on the movement o ...